NuVue Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
A game-changing, silver-bullet approach for diagnosing and treating soft-tissue cancers could replace traditional biopsy techniques and IV chemotherapy. Or so hopes NuVue Therapeutics Inc., which is developing a suite of products that could allow more precise tissue removal through an ultrasound-guided needle with color monitoring for easy visibility, plus reduce the current high rates of toxicity and morbidity associated with chemotherapy. The company says its technology enables very low-volume/highly concentrated dosing, just 1/200th to 1/500th of the standard dose of systemic chemotherapy.